Bioventus Inc. Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products

Reuters
07-31
<a href="https://laohu8.com/S/BVS">Bioventus Inc.</a> Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products

Bioventus Inc., a leader in active healing innovations, announced a major achievement on July 30, 2025, with the U.S. Food and Drug Administration (FDA) granting 510(k) clearances for its two next-generation Peripheral Nerve Stimulation $(PNS.UK)$ products, TalisMann™ and StimTrial™. These approvals mark a significant milestone for Bioventus, expanding its innovative PNS solutions aimed at chronic pain management. The company plans a limited commercial release in selected U.S. markets during the third quarter, with a broader rollout anticipated in early 2026. This development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies, presenting a substantial growth opportunity in a PNS market projected to exceed $500 million by 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioventus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001665988-25-000013), on July 31, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10